search for: therapies

We just studied randomized block design analysis in my statistics class, and I'm trying to learn how to do them in R. I'm trying to duplicate a case study example from my textbook [1]: > # Case Study 13.2.1, page 778 > cd <- c(8, 11, 9, 16, 24) > dp <- c(2, 1, 12, 11, 19) > lm <- c(-2, 0, 6, 2, 11) > table <- data.frame(Block=LETTERS[1:5], "Score

...o_lunga 40 50 124 4912 ormo_breve 40 50 124 4912 chemio_lunga 40 50 124 4532 ormo_breve 61 63 26 4532 ormo_breve 61 63 26 4532 chemio_lunga 61 63 26 I have a list of (short) series of states identified by the ID of the patient who undergoes several therapies. I then have other info about each patient (for instance its age when the disease was first detected and so on). The point is to calculate the transition matrix for the sequence of therapies undergone by the patients and then possibly use the complementary information available for the patien...

...ff Topic** Those interested in clinical trials may find the following of interest: http://www.nytimes.com/2010/09/19/health/research/19trial.html It concerns the ethicality of randomizing those with life-threatening disease to relatively ineffective SOC when new "biologically targeted" therapies "appear" to be more effective. While the context may be new, the debate, itself, is not: Tukey wrote (or maybe it was talked -- I can't remember for sure) about this about 30 years ago. I'm sure many other also have done so. Cheers, Bert -- Bert Gunter Genentech Nonclinical Bio...

COMPUTATIONAL ANALYSIS OF NEXT GENERATION SEQUENCE DATA (http://bioinformatics.nki.nl/vacancies.php) THREE BIOINFORMATICS POSITIONS PROJECT OUTLINE Genomic alterations are major determinant of responses to (targeted) therapies in cancer. In fact, the best positive and negative predictors of responses to targeted therapies are alterations in kinases or their direct downstream effectors. To gain insight into resistance mechanisms to therapy and thus better tailor treatment, we are approaching this problem from two differen...

Hi everyone, I have the following problem: I have three variables, 'group', 'city' and 'pressure' There is an interaction effect between group and city and I'd like to show this in an interaction plot: interaction.plot(group, city, pressure, type="b", col= c(1:2), leg.bty="o", leg.bg="blue", lwd=1,

...sly. If this might be of any possible link up with yourself or a student of yours, read on, otherwise reread Uwe's post or just hit the delete button! The situation is that I have co-developed a "copyleft" self-report measure that adult, tabloid literate clients in psychological therapies can complete readily that gives reasonable indication of their state say at referral, assessment, start of therapy, during therapy, end of therapy, follow-up etc. It's part of a system we call CORE (Clinical Outcomes in Routine Evaluation). How it is used is up to practitioners as our aim...

Hi, I am doing a retrospective analysis on a cohort from a designed trial, and I am fitting the model fit<-glmD(survived ~ Covariate*Therapy + confounder,myDat,X=TRUE, Y=TRUE, family=binomial()) My covariate has three levels ("A","B" and "C") and therapy has two (treated and control), confounder is a continuous variable. Also patients were randomized to

Dear R-helpers: I am trying to fit a multivariate Cox proportional hazards model, modelling survival outcome as a function of treatment and receptor status. The data look like below: # structure of the data str(sample.data) List of 4 $ survobj : Surv [1:129, 1:2] 0.8925+ 1.8836+ 2.1191+ 5.3744+ 1.6099+ 5.2567 0.2081+ 0.2108+ 0.2683+ 0.4873+ ... ..- attr(*, "dimnames")=List of 2

Hi all, I dumped my schema from SQLServer 2000 without any problems. I then tried to "rake db_schema_import" on MySQL 4. To do this i changed my database.yml settings to use the mysql adapter (as it was set to use sqlsever before) and attempted the import. I haven''t changed a thing in the schema.rb script and, even though I do have generated a migration, I think I

Dear I am analysing my data wit a mixed model. I used SAS but I want to redo the same analysis in R. Here the SAS code and what I wrote in R. It seems to work but the results are not the same. I don't know how to specify the class variable in R or specify the variance matrix. Can you please help me? Thanks Jurgen ## SAS: proc glimmix data=trend method=RSPL; class pid; model mdrfinal

Hi, >From idea to launch in less than 48 hours (those 48 hours including the new year party ;) , rails once again showed its effectiveness. Last friday I read the news about a guy who sold a million pixels for 1$ each on his homepage. After slamming my head during half an hour for not having thought of it [1], I thought I''d better spend some time on a rails project, and more as a

Is there anything in the Puppet/Passenger setup process that edits httpd.conf and sets the User/Group running apache to "puppet" ? A master I set up several months ago is configured that way. I do not recall doing it. But then the high voltage electroshock therapy does have its side effects :) “Sometimes I think the surest sign that intelligent life exists elsewhere in the

Hello, I need help in performing a Van_der_Waerden normal scores test in R. I have two arrays of scores(final on therapy scores from drug and placebo) and want to use the normal scores procdeure to test for significance. (observations are unequal in number - due to dropouts). Could you please help me out with the coding or let me know if there is a package that can be used (for example,

...ees the same and finds this helpful. Thanks to the R team, yet again, for an amazing product! Chris -- Chris Evans <chris at psyctc.org> Skype: chris-psyctc Consultant Psychiatrist in Psychotherapy, Notts. PDD network; Trust Research Governance Lead and Clinical Director, Psychological Therapies Directorate in Local Services, Nottinghamshire NHS Trust; Professor, Psychotherapy, Nottingham University *If I am writing from one of those roles, it will be clear. Otherwise* *my views are my own and not representative of those institutions * If you have difficulty Emailing me on this address...

Dear R-helpers: I am trying to fit a multivariate Cox proportional hazards model, modelling survival outcome as a function of treatment and receptor status. The data look like below: # structure of the data str(sample.data) List of 4 $ survobj : Surv [1:129, 1:2] 0.8925+ 1.8836+ 2.1191+ 5.3744+ 1.6099+ 5.2567 0.2081+ 0.2108+ 0.2683+ 0.4873+ ... ..- attr(*, "dimnames")=List of 2

Hi, I am wondering if there is a way to change the value of the "record" option in a graphics device that is already open (and accepts this option). I don''t want to open a new device with, for example "dev.new(record=T)", but just want to change the settings of the current device. This can be done by pointing and clicking on the "history" tab of a

Hello Everyone, I have what I think is a complex text parsing task. I've provided some sample data below. There's a relatively simple version of the coding that needs to be done and a more complex version. If someone could help me out with either version, I'd greatly appreciate it. Here are my sample data. haveData <- structure(list(profile_key = structure(c(1L, 1L, 2L, 2L, 2L,

[markdown format] I'm glad to introduce you the new package aVirtualTwins. This package is an adaptation of VirtualTwins method of subgroup identification from [Foster, J. C., Taylor, J. M.G. and Ruberg, S. J. (2011)](http://onlinelibrary.wiley.com/doi/10.1002/sim.4322/abstract). ### Explanation Virtual Twins has been created to find subgroup of patients in a random clinical trial with

[markdown format] I'm glad to introduce you the new package aVirtualTwins. This package is an adaptation of VirtualTwins method of subgroup identification from [Foster, J. C., Taylor, J. M.G. and Ruberg, S. J. (2011)](http://onlinelibrary.wiley.com/doi/10.1002/sim.4322/abstract). ### Explanation Virtual Twins has been created to find subgroup of patients in a random clinical trial with

Edwards Lifesciences (NYSE: EW) is a global leader in products and technologies to treat advanced cardiovascular disease, the global leader in acute hemodynamic monitoring and the number-one heart valve company in the world. Headquartered in Irvine, California, Edwards has more than 5,000 employees worldwide, selling medical technologies in more than 100 countries. Edwards Lifesciences leverages